Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Seach Medical Group Ltd specializes in the development and manufacturing of specialty pharmaceuticals, primarily targeting niche therapeutic areas such as oncology and rare diseases. The company operates primarily in Israel and has a competitive edge through its proprietary drug formulations and a strong pipeline of products awaiting regulatory approval.
Seach Medical generates revenue through the sale of specialty and generic pharmaceuticals, leveraging its proprietary drug formulations to command higher pricing power. The company's focus on niche markets allows it to maintain a competitive advantage despite the pressures of generic competition.
Regulatory approvals for new drug formulations
Market entry of competitors in specialty segments
Changes in healthcare policy affecting drug pricing
Partnerships or collaborations with larger pharmaceutical companies
Regulatory changes impacting drug approval processes
Technological disruption in drug development
Emergence of generic alternatives for specialty drugs
Increased competition from larger pharmaceutical firms
Low net income margin (1.0%) may limit financial flexibility
Dependence on successful product launches to drive revenue
low - The demand for specialty pharmaceuticals tends to be less sensitive to economic cycles as they often address critical health needs.
Minimal impact from interest rates as the company has low debt levels (Debt/Equity of 0.16), reducing financing costs. However, higher rates could affect overall healthcare spending.
minimal - The company operates with a low debt-to-equity ratio, indicating limited reliance on credit markets.
value - Investors may be drawn to the low valuation metrics (Price/Sales of 0.6x) and potential for turnaround given the company's niche focus.
moderate - Historical volatility is expected to be moderate due to the nature of the healthcare sector and the company's operational challenges.